FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer

Updated CRB-701 monotherapy data accepted for presentation at ASCO 2026

Dr. Dominic Smethurst to step down as Corbus' Chief Medical Officer on June 30, 2026